Pharmacogenetics of warfarin: current status and future challenges (Q36597343)

15 August 2017

1 reference

title

Pharmacogenetics of warfarin: current status and future challenges (English)

1 reference

15 August 2017

1 reference

M Pirmohamed

0 references

M Wadelius

1 reference

15 August 2017

publication date

19 September 2006

1 reference

The Pharmacogenomics Journal

15 August 2017

published in

1 reference

15 August 2017

1 reference

15 August 2017

1 reference

15 August 2017

page(s)

99-111

1 reference

Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Interindividual variability in sensitivity to warfarin--Nature or nurture?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Major bleeding complications in a specialized anticoagulation service

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Pharmacogenetics of oral anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Differential binding of disopyramide and warfarin enantiomers to human alpha(1)-acid glycoprotein variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms: high-speed screening and structure-activity relationship analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Efflux transporters and their clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Clinical consequences of cytochrome P450 2C9 polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Genetic mechanisms for hypersensitivity and resistance to the anticoagulant Warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Pharmacogenetics of warfarin elimination and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Human P450 metabolism of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Several-fold increase in risk of overanticoagulation by CYP2C9 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Clinical relevance of genetic polymorphisms in the human CYP2C9 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Extreme warfarin sensitivity in siblings associated with multiple cytochrome P450 polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Evidence of significant contribution from CYP3A5 to hepatic drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Genetic regulation of warfarin metabolism and response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Induction of Human CYP2C9 by Rifampicin, Hyperforin, and Phenobarbital Is Mediated by the Pregnane X Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Interleukin 1beta inhibits CAR-induced expression of hepatic genes involved in drug and bilirubin clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Medicine: K is for koagulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Warfarin dose related to apolipoprotein E (APOE) genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Patients with an ApoE epsilon4 allele require lower doses of coumarin anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Apolipoprotein E (APOE) and warfarin dosing in an Italian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Identification of the gene for vitamin K epoxide reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Compound heterozygous mutations in the gamma-glutamyl carboxylase gene cause combined deficiency of all vitamin K-dependent blood coagulation factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Warfarin treatment of a patient with coagulation factor IX propeptide mutation causing warfarin hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Non-fatal major bleeding during treatment with vitamin K antagonists: influence of soluble thrombomodulin and mutations in the propeptide of coagulation factor IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Decline of proteins C and S and factors II, VII, IX and X during the initiation of warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Warfarin induced skin necrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Effect of anticoagulant therapy on the hypercoagulable state in patients carrying the factor V Arg506Gln mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Early evaluation of hematuria in a patient receiving anticoagulant therapy and detection of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Multiple progressive intracerebral hemorrhages due to an angiosarcoma: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Inherited disorders of platelets: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Home prothrombin time monitoring: a literature analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Cytochrome P450 polymorphisms are associated with reduced warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Review of computerized decision support systems for oral anticoagulation management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

Genetic association between sensitivity to warfarin and expression of CYP2C9*3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

7 January 2021

CYP2C9*3 allelic variant and bleeding complications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

7 January 2021

A comparative study of the interaction of warfarin with human alpha 1-acid glycoprotein and human albumin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

7 January 2021

The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

7 January 2021

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

7 January 2021

Mechanism of action of warfarin. Warfarin and metabolism of vitamin K 1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

7 January 2021

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

7 January 2021

Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

7 January 2021

Transport of vitamin K to bone in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

7 January 2021

Plasma lipoproteins as carriers of phylloquinone (vitamin K1) in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

7 January 2021

Phylloquinone transport and its influence on gamma-carboxyglutamate residues of osteocalcin in patients on maintenance hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

7 January 2021

Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

7 January 2021

Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

7 January 2021

Assembly of the Warfarin-sensitive Vitamin K 2,3-Epoxide Reductase Enzyme Complex in the Endoplasmic Reticulum Membrane

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

7 January 2021

Co-purification of Microsomal Epoxide Hydrolase with the Warfarin-Sensitive Vitamin K1 Oxide Reductase of the Vitamin K Cycle

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

7 January 2021

The vitamin K-dependent carboxylase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

7 January 2021

A missense mutation in gamma-glutamyl carboxylase gene causes combined deficiency of all vitamin K-dependent blood coagulation factors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

7 January 2021

A molecular mechanism for genetic warfarin resistance in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

7 January 2021

Coumarin necrosis associated with hereditary protein C deficiency

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

7 January 2021

Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS) Collaborators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

7 January 2021

Warfarin dosing and cytochrome P450 2C9 polymorphisms.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

7 January 2021

The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

7 January 2021

The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

7 January 2021

The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

7 January 2021

Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500417

7 January 2021

Identifiers

DOI

10.1038/SJ.TPJ.6500417

1 reference

15 August 2017

1 reference